ZA200409901B - Medicinal compositions improving brain function and method for improving brain function - Google Patents
Medicinal compositions improving brain function and method for improving brain functionInfo
- Publication number
- ZA200409901B ZA200409901B ZA200409901A ZA200409901A ZA200409901B ZA 200409901 B ZA200409901 B ZA 200409901B ZA 200409901 A ZA200409901 A ZA 200409901A ZA 200409901 A ZA200409901 A ZA 200409901A ZA 200409901 B ZA200409901 B ZA 200409901B
- Authority
- ZA
- South Africa
- Prior art keywords
- brain function
- improving brain
- cerebral
- ingredient
- integer
- Prior art date
Links
- 230000003925 brain function Effects 0.000 title 2
- 239000000203 mixture Substances 0.000 title 1
- 230000002490 cerebral effect Effects 0.000 abstract 3
- 239000004615 ingredient Substances 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004373 acetylcholine Drugs 0.000 abstract 1
- 150000005215 alkyl ethers Chemical class 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 208000013677 cerebrovascular dementia Diseases 0.000 abstract 1
- 229960003530 donepezil Drugs 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000016273 neuron death Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960001685 tacrine Drugs 0.000 abstract 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002173483 | 2002-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200409901B true ZA200409901B (en) | 2006-07-26 |
Family
ID=29727916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200409901A ZA200409901B (en) | 2002-06-14 | 2004-12-07 | Medicinal compositions improving brain function and method for improving brain function |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | USRE42327E1 (da) |
| EP (2) | EP2389937B1 (da) |
| JP (1) | JP4675103B2 (da) |
| KR (1) | KR100935615B1 (da) |
| CN (1) | CN100375619C (da) |
| AT (1) | ATE546140T1 (da) |
| AU (1) | AU2003236364C1 (da) |
| BR (1) | BRPI0311780B8 (da) |
| CA (1) | CA2488120C (da) |
| CY (2) | CY1112958T1 (da) |
| DK (2) | DK1514542T3 (da) |
| ES (2) | ES2685923T3 (da) |
| HU (1) | HUE041842T2 (da) |
| IL (1) | IL165589A (da) |
| MX (1) | MXPA04012534A (da) |
| NO (1) | NO333504B1 (da) |
| NZ (1) | NZ537090A (da) |
| PL (1) | PL217394B1 (da) |
| PT (2) | PT1514542E (da) |
| SI (2) | SI2389937T1 (da) |
| TR (1) | TR201816386T4 (da) |
| WO (1) | WO2003105830A1 (da) |
| ZA (1) | ZA200409901B (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1437353E (pt) * | 2001-10-19 | 2007-08-28 | Toyama Chemical Co Ltd | Derivados de éter de alquilo ou os seus sais. |
| ES2685923T3 (es) | 2002-06-14 | 2018-10-15 | Toyama Chemical Co., Ltd. | Composición medicinal para mejorar la función cerebral |
| US20060205709A1 (en) * | 2003-04-17 | 2006-09-14 | Toyama Chemical Co., Ltd. | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
| US7435837B2 (en) | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| EP2258358A3 (en) * | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| PL2011796T3 (pl) * | 2006-04-26 | 2015-03-31 | Toyama Chemical Co Ltd | Induktor neurogenezy lub środek terapeutyczny do stosowania w neuropatii zawierający pochodną eteru alkilowego lub jej sól |
| US8119625B2 (en) * | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| CA2659835A1 (en) * | 2006-08-04 | 2008-02-07 | Toyama Chemical Co., Ltd. | Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| DK2287160T3 (da) * | 2008-05-28 | 2014-06-10 | Toyama Chemical Co Ltd | Benzothiophenoxidderivat og salt deraf |
| CA2908929C (en) | 2012-07-12 | 2021-01-26 | Concert Pharmaceuticals, Inc. | Deuterated idebenone |
| JP5837726B1 (ja) * | 2014-01-31 | 2015-12-24 | 富山化学工業株式会社 | アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤 |
| JP7282028B2 (ja) | 2017-06-02 | 2023-05-26 | 富士フイルム富山化学株式会社 | 脳萎縮予防または治療剤 |
| CN110691593B (zh) | 2017-06-02 | 2023-05-02 | 富士胶片富山化学株式会社 | 脊髓小脑变性症预防或治疗剂 |
| CN110691594A (zh) | 2017-06-02 | 2020-01-14 | 富士胶片富山化学株式会社 | Tau蛋白病预防或治疗剂 |
| US11666551B2 (en) | 2017-06-02 | 2023-06-06 | Fujifilm Toyama Chemical Co., Ltd. | Agent for reducing amount of amyloid β protein |
| EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA |
| AU2018301222A1 (en) * | 2017-07-08 | 2020-01-30 | The General Hospital Corporation | Screening platform to identify therapeutic drugs or agents for treatment of alzheimer's disease |
| WO2019088083A1 (ja) | 2017-10-30 | 2019-05-09 | 富士フイルム富山化学株式会社 | エモパミル結合タンパク質結合剤およびその利用 |
| CN110464834B (zh) * | 2019-09-04 | 2022-12-02 | 北京豪思生物科技股份有限公司 | 铜蓝蛋白联合多奈哌齐的应用 |
| KR20220040291A (ko) | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 4-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
| KR20220040294A (ko) | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| US5177082A (en) | 1985-11-05 | 1993-01-05 | Yu Chao Mei | Huperzines and analogs |
| US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| JPH0210827A (ja) | 1988-06-29 | 1990-01-16 | Matsushita Electron Corp | 半導体装置の製造方法 |
| US5280032A (en) | 1989-02-14 | 1994-01-18 | Toyama Chemical Co., Ltd. | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same |
| JP2913196B2 (ja) | 1989-04-26 | 1999-06-28 | 富山化学工業株式会社 | １，２−エタンジオール誘導体またはその塩 |
| NZ232493A (en) * | 1989-02-14 | 1992-06-25 | Toyama Chemical Co Ltd | Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions |
| JP2887492B2 (ja) | 1990-02-05 | 1999-04-26 | 富山化学工業株式会社 | １，２―エタンジオール誘導体およびその塩 |
| US4914102A (en) * | 1989-09-28 | 1990-04-03 | Hoechst Roussel Pharmaceuticals, Inc. | N-aminocarbamates related to physostigmine, pharmacentical compositions and use |
| JP3044055B2 (ja) * | 1990-08-09 | 2000-05-22 | 富山化学工業株式会社 | １，２―エタンジオール誘導体およびその塩 |
| JPH0676401B2 (ja) | 1990-10-19 | 1994-09-28 | エスエス製薬株式会社 | キノリン誘導体及びこれを含有する医薬 |
| TW197435B (da) | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
| DE4111861A1 (de) | 1991-04-11 | 1992-10-15 | Schwabe Willmar Gmbh & Co | Benzopyranone, verfahren zu ihrer herstellung und verwendung |
| JP2925363B2 (ja) | 1991-07-09 | 1999-07-28 | キヤノン株式会社 | 画像処理方法及び装置 |
| DE4136288A1 (de) | 1991-11-04 | 1993-05-06 | Troponwerke Gmbh & Co Kg, 5000 Koeln, De | Kombination von calciumantagonisten mit cholinesterase-inhibitoren |
| JP3232830B2 (ja) | 1993-11-30 | 2001-11-26 | 三菱電機株式会社 | フレキシブルディスク装置のキャリッジ機構 |
| PL187004B1 (pl) | 1994-10-25 | 2004-04-30 | Toyama Chemical Co Ltd | Nowe pochodne 1,2-etanodiolu oraz kompozycje farmaceutyczne je zawierające |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| AU1672597A (en) * | 1996-02-20 | 1997-09-10 | Toyama Chemical Co. Ltd. | Cerebral function ameliorant containing 1,2-ethanediol derivatives or salts thereof |
| HUP9904622A3 (en) * | 1996-07-10 | 2001-07-30 | Schering Corp | 1,4-di-sustituted piperidines as muscarinic antagonists |
| ATE297381T1 (de) * | 1996-08-15 | 2005-06-15 | Schering Corp | Ether-muskarinantagonisten |
| JPH10259126A (ja) | 1997-01-17 | 1998-09-29 | Takeda Chem Ind Ltd | アルツハイマー病治療・予防剤 |
| CO4980891A1 (es) | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
| US20030092737A1 (en) | 1997-11-14 | 2003-05-15 | Pierre Maffrand Jean | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type |
| WO1999031056A1 (fr) | 1997-12-12 | 1999-06-24 | Toyama Chemical Co., Ltd. | Derives d'ether alcoylique ou leurs sels, et antagonistes du calcium les contenant |
| CZ302083B6 (cs) * | 1999-06-11 | 2010-09-29 | Toyama Chemical Co., Ltd. | N-Alkoxyalkyl-N, N-dialkylaminový derivát nebo jeho sul a farmaceutická kompozice s jeho obsahem pro lécení neurodegenerativních chorob |
| PT1437353E (pt) | 2001-10-19 | 2007-08-28 | Toyama Chemical Co Ltd | Derivados de éter de alquilo ou os seus sais. |
| ES2685923T3 (es) | 2002-06-14 | 2018-10-15 | Toyama Chemical Co., Ltd. | Composición medicinal para mejorar la función cerebral |
| US20060205709A1 (en) | 2003-04-17 | 2006-09-14 | Toyama Chemical Co., Ltd. | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
| PL2011796T3 (pl) | 2006-04-26 | 2015-03-31 | Toyama Chemical Co Ltd | Induktor neurogenezy lub środek terapeutyczny do stosowania w neuropatii zawierający pochodną eteru alkilowego lub jej sól |
| US8119625B2 (en) | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
-
2003
- 2003-04-03 ES ES11006318.7T patent/ES2685923T3/es not_active Expired - Lifetime
- 2003-04-03 AT AT03760132T patent/ATE546140T1/de active
- 2003-04-03 NZ NZ537090A patent/NZ537090A/en not_active IP Right Cessation
- 2003-04-03 CN CNB038138573A patent/CN100375619C/zh not_active Expired - Lifetime
- 2003-04-03 JP JP2004512734A patent/JP4675103B2/ja not_active Expired - Lifetime
- 2003-04-03 CA CA2488120A patent/CA2488120C/en not_active Expired - Lifetime
- 2003-04-03 EP EP11006318.7A patent/EP2389937B1/en not_active Expired - Lifetime
- 2003-04-03 HU HUE11006318A patent/HUE041842T2/hu unknown
- 2003-04-03 SI SI200332578T patent/SI2389937T1/sl unknown
- 2003-04-03 WO PCT/JP2003/004292 patent/WO2003105830A1/ja active Application Filing
- 2003-04-03 KR KR1020047020053A patent/KR100935615B1/ko active IP Right Grant
- 2003-04-03 BR BRPI0311780A patent/BRPI0311780B8/pt not_active IP Right Cessation
- 2003-04-03 ES ES03760132T patent/ES2379948T3/es not_active Expired - Lifetime
- 2003-04-03 US US12/683,813 patent/USRE42327E1/en not_active Expired - Lifetime
- 2003-04-03 IL IL165589A patent/IL165589A/en active IP Right Grant
- 2003-04-03 PT PT03760132T patent/PT1514542E/pt unknown
- 2003-04-03 MX MXPA04012534A patent/MXPA04012534A/es active IP Right Grant
- 2003-04-03 TR TR2018/16386T patent/TR201816386T4/tr unknown
- 2003-04-03 SI SI200332141T patent/SI1514542T1/sl unknown
- 2003-04-03 DK DK03760132.5T patent/DK1514542T3/da active
- 2003-04-03 PL PL372934A patent/PL217394B1/pl unknown
- 2003-04-03 DK DK11006318.7T patent/DK2389937T3/da active
- 2003-04-03 PT PT11006318T patent/PT2389937T/pt unknown
- 2003-04-03 EP EP03760132A patent/EP1514542B1/en not_active Expired - Lifetime
- 2003-04-03 AU AU2003236364A patent/AU2003236364C1/en not_active Expired
- 2003-04-03 US US10/516,320 patent/US7342043B2/en not_active Ceased
-
2004
- 2004-11-25 NO NO20045158A patent/NO333504B1/no not_active IP Right Cessation
- 2004-12-07 ZA ZA200409901A patent/ZA200409901B/xx unknown
-
2007
- 2007-12-17 US US11/957,832 patent/US7834053B2/en not_active Expired - Lifetime
-
2012
- 2012-05-08 CY CY20121100432T patent/CY1112958T1/el unknown
-
2018
- 2018-08-21 CY CY181100871T patent/CY1120591T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120591T1 (el) | Ιατρικη συνθεση για βελτιωση λειτουργιας εγκεφαλου | |
| BG105365A (en) | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | |
| PT1259489E (pt) | Compostos azapoliciclicos condensados con arilo. | |
| UA83899C2 (uk) | Сполуки імідазолу для лікування нейродегенеративних розладів | |
| HUP0101281A2 (hu) | Glicin transzport inhibitor hatású difenil-piperidin-butánamid-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények | |
| MY140835A (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| CA2534532A1 (en) | Compounds for the treatment of neurodegenerative disorders | |
| DE69033369T2 (de) | 1,2,3,4-Tetrahydro-9-Akridinamine-Derivate | |
| TW200509933A (en) | Therapeutic agents | |
| HU9400132D0 (en) | Tricyclic condensed heterocyclic compounds, process for producing them and pharmaceutical compositions contaning them as active component | |
| WO2005095348A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
| DE60231054D1 (de) | Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält | |
| WO2005095361A8 (en) | Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders | |
| NO891071D0 (no) | Fremgangsmaate for fremstilling av 4,5,6,7-tetrahydro-isotiazolo(4,5-c)-pyridinderivater og isomere. | |
| ATE423093T1 (de) | Neue mao-b-hemmer | |
| DK0950053T3 (da) | Hidtil ukendte benzoylalkyl.1,2,3,6-tetrahydropyridinderivater |